Evidence map›Paper›PMID 26195067›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2015

Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.

Fei Chen, Chuming Fan, Xuezhong Gu, Haixi Zhang, Qian Liu, Xiaoli Gao, Jie Lu, Baoli He, Xun Lai

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. 4-1BB agonism: adding the accelerator to cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Fei ChenDepartment of Nephrology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
Chuming FanIntensive Care Unit, Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
Xuezhong GuDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
Haixi ZhangDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
Qian LiuDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
Xiaoli GaoDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
Jie LuDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
Baoli HeAnimal Laboratory, Kunming Medical University, Kunming, Yunnan, China (mainland).
Xun LaiDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).
First People's Hospital of Yunnan Province · CNKunming Medical University · CNSecond People's Hospital of Yunnan Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy has been explored as a new therapy for B cell lymphoma, which is a non-Hodgkin's lymphoma. Because CD20 is a B lymphocyte-specific marker, anti-CD20 single chain-tagged T lymphocytes have already begun to be experimentally used in B cell lymphoma treatment, but its use is still limited because of its unspecific targeting. T cells transfected with CD28 and CD137 can significantly improve the ability of cytokines secretion and anti-tumor effect, as well as extending T cell survival time and improving their proliferation ability. MATERIAL AND

methodsGenes containing anti-CD20-CD28-CD137-TCRζ were constructed. After cloning and sequencing, the plasmid was constructed and packaged by lentivirus. It was transfected to the peripheral blood T lymphocyte after identification transfection to induce the fusion protein expression. The cells were incubated with Raji cells and the LDH test was performed to detect the cytotoxic effect of CAR-T cells; the tumor volume and survival rate were measured to observe its inhibitory effect on B cell lymphoma in nude mice.

resultsGene with anti-CD20-CD28-CD137-TCRζ was successfully constructed and transfected to the T cell surface. LDH assay revealed that CAR-T cells can kill the Raji cells with a killing rate of 32.89±6.26%. It can significantly inhibit B cell lymphoma growth in nude mice.

conclusionsT lymphocytes transfected with anti-CD20-CD28-CD137-TCRζ fusion gene can kill B cell lymphoma, which could provide a new strategy for tumor treatment.

Indexed as

AnimalsAntigens, CDAntigens, CD20CD28 AntigensCD4-Positive T-LymphocytesGene FusionHEK293 CellsHumansImmunotherapy, AdoptiveLymphoma, B-CellMiceMice, NudeRandom AllocationReceptors, Antigen, T-CellRecombination, GeneticSingle-Chain AntibodiesAntigens, CDAntigens, CD20antigen T cell receptor, zeta chainCD28 AntigensReceptors, Antigen, T-CellSingle-Chain AntibodiesTumor Necrosis Factor Receptor Superfamily, Member 9

Identifiers

PMID26195067
PMCPMC4537073
OpenAlexW1951679451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.